Teacher Retirement System of Texas Has $277.07 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Teacher Retirement System of Texas raised its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 335,468 shares of the company's stock after purchasing an additional 33,055 shares during the period. Eli Lilly and Company accounts for approximately 1.2% of Teacher Retirement System of Texas' holdings, making the stock its 10th biggest holding. Teacher Retirement System of Texas' holdings in Eli Lilly and Company were worth $277,066,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Garner Asset Management Corp boosted its holdings in Eli Lilly and Company by 2.3% during the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company's stock worth $411,000 after buying an additional 12 shares during the last quarter. Brighton Jones LLC raised its position in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after acquiring an additional 40 shares during the period. SOA Wealth Advisors LLC. boosted its stake in Eli Lilly and Company by 7.1% during the 4th quarter. SOA Wealth Advisors LLC. now owns 925 shares of the company's stock worth $714,000 after acquiring an additional 61 shares during the last quarter. Finally, Orion Capital Management LLC grew its holdings in Eli Lilly and Company by 2.5% during the fourth quarter. Orion Capital Management LLC now owns 1,610 shares of the company's stock valued at $1,243,000 after purchasing an additional 40 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.0%

Shares of Eli Lilly and Company stock traded up $0.32 on Friday, reaching $779.60. 1,450,772 shares of the company were exchanged, compared to its average volume of 3,664,838. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company has a 50-day moving average of $775.72 and a 200 day moving average of $799.71. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company has a market capitalization of $738.85 billion, a price-to-earnings ratio of 63.43, a PEG ratio of 1.14 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. Eli Lilly and Company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same period last year, the firm earned $2.58 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target on the stock. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Guggenheim restated a "buy" rating and issued a $936.00 price target on shares of Eli Lilly and Company in a report on Friday, June 20th. Finally, HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price target for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.